AbbVie’s Phase III induction study, U-ACHIEVE, of Rinvoq (upadacitinib) in moderate to severe ulcerative colitis hit the primary endpoint of clinical remission at week 8 and also met all ranked secondary endpoints.
BioSpace Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More
3D, Antibody-Drug Conjugates (ADCs), Business, Clinical Trials, Collaborations, Coronavirus Disease 2019 (COVID-19), Data, E. Coli, Fast Track Designation, FDA, Gene Editing, Joint Ventures, Licensing, Metastatic pancreatic cancer, Neurological Disorders, R&D, Series A, Small cell lung cancer, Staphylococcus aureus infections, Therapeutics, Ulcerative Colitis, VaccinesParis-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.
Roche Holding’s experimental drug etrolizumab did not fare well in late-stage clinical trials in treating people with moderate to severe ulcerative colitis, the Swiss drugmaker said.
FDA Action Alert: Jazz, ANI and Ultragenyx
Approvals, Cataplexy, Excessive Daytime Sleepiness, Fatty Acids, FDA, FDA/Regulatory, Gels, Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD), Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD), Multiple Sclerosis, Narcolepsy, New Drug Applications, PDUFA, Refusal to File letter, Rheumatoid Arthritis, Supplemental New Drug Application (sNDA), Systemic Lupus Erythematosus (SLE), Ulcerative ColitisU.S. Food and Drug Administration PDUFA dates on the calendar for July include an NDA review for Jazz Pharmaceuticals’ experimental medicine for cataplexy.
One day after Bristol Myers Squibb announced the commercial launch of the multiple sclerosis drug Zeposia (ozanimod), the company said the medication demonstrated statistically significant efficacy as a potential induction and maintenance therapy for ulcerative colitis.
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences Inc. and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
Researchers Working to Understand Why Some Patients with Autoimmune Diseases Develop Diabetes Instead of Arthritis
Arthritis, Autoimmune Diseases, Autoimmune inflammation, Beta cells, Diabetes, Genes, Immune Cells, Inflammatory Bowel Disease, Insulin, Multiple Sclerosis, National Institutes of Health, Nature Genetics, Pancreatic beta cells, Pluripotential cells, Researchers, Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Type 1 DiabetesRecently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?
The U.S. Food and Drug Administration approved Janssen’s Stelara (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis.
Japan’s Takeda Pharmaceutical presented more data from the company’s Phase IIIb head-to-head VARSITY clinical trial of Entyvio compared to AbbVie’s Humira in ulcerative colitis.